Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Company profile
Ticker
CNCE
Exchange
Website
CEO
Roger Tung
Employees
Location
Fiscal year end
Industry (SIC)
Former names
CONCERT PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Concert Pharmaceuticals Securities Corp. • Concert Pharma U.K. Ltd • Concert Pharma Ireland Limited ...
CNCE stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
16 Mar 23
EFFECT
Notice of effectiveness
14 Mar 23
EFFECT
Notice of effectiveness
14 Mar 23
EFFECT
Notice of effectiveness
14 Mar 23
EFFECT
Notice of effectiveness
14 Mar 23
25-NSE
Exchange delisting
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
Transcripts
CNCE
Earnings call transcript
2022 Q3
7 Nov 22
CNCE
Earnings call transcript
2022 Q2
6 Aug 22
CNCE
Earnings call transcript
2022 Q1
7 May 22
CNCE
Earnings call transcript
2021 Q4
3 Mar 22
CNCE
Earnings call transcript
2021 Q3
9 Nov 21
CNCE
Earnings call transcript
2021 Q2
8 Aug 21
CNCE
Earnings call transcript
2021 Q1
4 May 21
CNCE
Earnings call transcript
2020 Q4
28 Feb 21
CNCE
Earnings call transcript
2020 Q3
8 Nov 20
CNCE
Earnings call transcript
2020 Q2
9 Aug 20
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 96.35 mm | 96.35 mm | 96.35 mm | 96.35 mm | 96.35 mm | 96.35 mm |
Cash burn (monthly) | 14.69 mm | 706.25 k | 9.87 mm | 10.36 mm | 8.65 mm | 9.14 mm |
Cash used (since last report) | 274.39 mm | 13.20 mm | 184.39 mm | 193.49 mm | 161.67 mm | 170.75 mm |
Cash remaining | -178.05 mm | 83.15 mm | -88.05 mm | -97.15 mm | -65.33 mm | -74.41 mm |
Runway (months of cash) | -12.1 | 117.7 | -8.9 | -9.4 | -7.5 | -8.1 |
Institutional ownership, Q1 2023
7.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 80 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 4.92 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 4.92 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 23 | Aldrich Richard | Common Stock | Dispose U | Yes | No | 0 | 44,351 | 0.00 | 0 | |
6 Mar 23 | Aldrich Richard | Common Stock | Dispose U | Yes | No | 0 | 210,526 | 0.00 | 0 | |
6 Mar 23 | Aldrich Richard | Common Stock | Sale back to company | Dispose D | No | No | 0 | 16,400 | 0.00 | 0 |
6 Mar 23 | Aldrich Richard | Common Stock | Dispose U | No | No | 0 | 342,100 | 0.00 | 0 | |
6 Mar 23 | Aldrich Richard | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5 | 22,410 | 112.05 k | 0 |
6 Mar 23 | Aldrich Richard | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.26 | 40,432 | 172.24 k | 0 |
6 Mar 23 | Aldrich Richard | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.16 | 23,260 | 213.06 k | 0 |
6 Mar 23 | Aldrich Richard | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 11.02 | 10,000 | 110.20 k | 0 |
6 Mar 23 | Aldrich Richard | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 19.59 | 15,940 | 312.26 k | 0 |
6 Mar 23 | Aldrich Richard | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 13.29 | 10,000 | 132.90 k | 0 |